A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

Donna E. Reece,Nizar J. Bahlis,Christy Samaras,Michael Sebag,Jesus G. Berdeja,S. Ganguly,Jeffrey Matous,Kevin W. Song,Christopher S. Seet,Giampaolo Talamo,Mirelis Acosta-Rivera,Michael Bar,Donald P. Quick,Bertrand Anz,Gustavo A. Fonseca,Amit Agarwal,Weiyuan Chung,Faiza Zafar,David S. Siegel

A health-related quality-of-life (HRQoL) analysis of pomalidomide + low-dose dexamethasone + daratumumab in relapsed refractory multiple myeloma (RRMM) after lenalidomide treatment.

2019

Donna E. Reece
Nizar J. Bahlis
Christy Samaras
Michael Sebag
Jesus G. Berdeja
S. Ganguly
Jeffrey Matous
Kevin W. Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald P. Quick
Bertrand Anz
Gustavo A. Fonseca
Amit Agarwal
Weiyuan Chung
Faiza Zafar
David S. Siegel

8025Background: Treatment (Tx) of RRMM is complex and requires evaluation of disease and patient (pt) factors to maximize efficacy and minimize toxicity. HRQoL has become an important aspect of MM ...

Keywords:

Pomalidomide
Physical therapy
Refractory Multiple Myeloma
Toxicity
Lenalidomide
Dexamethasone
Daratumumab
Disease
Oncology
Internal medicine
Quality of life
Medicine
health related quality of life
Multiple myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations